[
  {
    "ts": "2025-10-29T22:16:49+00:00",
    "headline": "Liver Drug Approval and Pipeline Data Could Be a Game Changer for Gilead Sciences (GILD)",
    "summary": "In recent weeks, Gilead Sciences announced Health Canada's conditional approval of LYVDELZI (seladelpar) for primary biliary cholangitis, and presented new positive clinical data across its liver disease and oncology pipeline at major global conferences. This wave of regulatory and clinical milestones underscores Gilead's momentum in diversifying beyond its HIV franchise with late-stage therapies addressing major unmet needs. We'll examine how Health Canada’s approval for LYVDELZI and strong...",
    "url": "https://finance.yahoo.com/news/liver-drug-approval-pipeline-data-221649730.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "eceedde6-f023-377e-b4c3-b949bf65cde6",
      "content": {
        "id": "eceedde6-f023-377e-b4c3-b949bf65cde6",
        "contentType": "STORY",
        "title": "Liver Drug Approval and Pipeline Data Could Be a Game Changer for Gilead Sciences (GILD)",
        "description": "",
        "summary": "In recent weeks, Gilead Sciences announced Health Canada's conditional approval of LYVDELZI (seladelpar) for primary biliary cholangitis, and presented new positive clinical data across its liver disease and oncology pipeline at major global conferences. This wave of regulatory and clinical milestones underscores Gilead's momentum in diversifying beyond its HIV franchise with late-stage therapies addressing major unmet needs. We'll examine how Health Canada’s approval for LYVDELZI and strong...",
        "pubDate": "2025-10-29T22:16:49Z",
        "displayTime": "2025-10-29T22:16:49Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HAEiJmFsYXJTRBPxnneP6w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hXB9F2qU7k4qk3_k1DQd9A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/liver-drug-approval-pipeline-data-221649730.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/liver-drug-approval-pipeline-data-221649730.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-29T20:11:00+00:00",
    "headline": "Victory! AHF, 100 Organizations Kill Gilead’s Greedy Drug Price Hikes",
    "summary": "WASHINGTON, October 29, 2025--Victory! AHF, 100 Organizations Kill Gilead’s Greedy Drug Price Hikes",
    "url": "https://finance.yahoo.com/news/victory-ahf-100-organizations-kill-201100176.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "5d8f13f4-3131-380b-b13b-95203fbf8ef3",
      "content": {
        "id": "5d8f13f4-3131-380b-b13b-95203fbf8ef3",
        "contentType": "STORY",
        "title": "Victory! AHF, 100 Organizations Kill Gilead’s Greedy Drug Price Hikes",
        "description": "",
        "summary": "WASHINGTON, October 29, 2025--Victory! AHF, 100 Organizations Kill Gilead’s Greedy Drug Price Hikes",
        "pubDate": "2025-10-29T20:11:00Z",
        "displayTime": "2025-10-29T20:11:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/victory-ahf-100-organizations-kill-201100176.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/victory-ahf-100-organizations-kill-201100176.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-29T12:58:00+00:00",
    "headline": "Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings?",
    "summary": "Gilead Sciences gears up for Q3 results with strong HIV gains and new FDA approvals, amid challenges in its Cell Therapy business.",
    "url": "https://finance.yahoo.com/news/buy-hold-sell-gild-stock-125800909.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "f6af8322-e0a1-30fd-ad58-b5698007d947",
      "content": {
        "id": "f6af8322-e0a1-30fd-ad58-b5698007d947",
        "contentType": "STORY",
        "title": "Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings?",
        "description": "",
        "summary": "Gilead Sciences gears up for Q3 results with strong HIV gains and new FDA approvals, amid challenges in its Cell Therapy business.",
        "pubDate": "2025-10-29T12:58:00Z",
        "displayTime": "2025-10-29T12:58:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/7de283b2224f57ff914c609b38092b2c",
          "originalWidth": 620,
          "originalHeight": 413,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Rsglp9DcmN3_7BlBHZoXjg--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7de283b2224f57ff914c609b38092b2c.cf.webp",
              "width": 620,
              "height": 413,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uDSo4QJoyaPL6uIXq9MpVA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7de283b2224f57ff914c609b38092b2c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/buy-hold-sell-gild-stock-125800909.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/buy-hold-sell-gild-stock-125800909.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "GLAXF"
            },
            {
              "symbol": "GSK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-29T03:13:42+00:00",
    "headline": "Gilead Sciences (GILD) Reports Q3: Everything You Need To Know Ahead Of Earnings",
    "summary": "Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results this Thursday after market close. Here’s what to expect.",
    "url": "https://finance.yahoo.com/news/gilead-sciences-gild-reports-q3-031342408.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "09ae8a23-dc0d-3b14-8887-66e0f01914f5",
      "content": {
        "id": "09ae8a23-dc0d-3b14-8887-66e0f01914f5",
        "contentType": "STORY",
        "title": "Gilead Sciences (GILD) Reports Q3: Everything You Need To Know Ahead Of Earnings",
        "description": "",
        "summary": "Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results this Thursday after market close. Here’s what to expect.",
        "pubDate": "2025-10-29T03:13:42Z",
        "displayTime": "2025-10-29T03:13:42Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/0c2e68ead77a9450e1fb435ed236802c",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "GILD Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7IhZSScYZ4CvnQJJpve_Dg--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/0c2e68ead77a9450e1fb435ed236802c.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cv.0mSrHV7hG2Zeh2xc10A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/0c2e68ead77a9450e1fb435ed236802c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-gild-reports-q3-031342408.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-gild-reports-q3-031342408.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]